<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02487849</url>
  </required_header>
  <id_info>
    <org_study_id>HIPEC-OVAR-REZIDIV-2014-1.1</org_study_id>
    <secondary_id>2015-002436-41</secondary_id>
    <nct_id>NCT02487849</nct_id>
  </id_info>
  <brief_title>HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma</brief_title>
  <acronym>HIPEC</acronym>
  <official_title>Feasability of an Unique Intraoperative Given Hyperthermal Intraperitoneal Chemotherapy With Carboplatin During a Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Krankenhaus Barmherzige Schwestern Linz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Krankenhaus Barmherzige Schwestern Linz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The combination of optimal cytoreductive operation (according to Desktop II criteria), HIPEC&#xD;
      with Carboplatin 800 mg/m² KOF (Körperoberfläche) and following platinum-based systemic&#xD;
      chemotherapy should be executed In patients with platinum-sensitive recurrence of ovarian&#xD;
      carcinoma. Condition for HIPEC is attainment of optimal cytoreduction (R0) and experts&#xD;
      judgement of a complication-free prolongation of narcosis after finishing the surgery. HIPEC&#xD;
      will be administered additionally to standard therapy. If HIPEC was executed the number of&#xD;
      systemic given platinum-based chemotherapy decreases for one cycle.&#xD;
&#xD;
      This regime should be investigated in terms of safety of performance, quality of life for the&#xD;
      patients and consequences for the following systemic chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In occurence with a platinum-sensitive recurrence of EOC survival can be prolonged by a&#xD;
      recurrence-operation, if macroscopical tumor-free status (optimal cytoreductive operation)&#xD;
      can be reached in combination with a platinum-based standard-chemotherapy.&#xD;
&#xD;
      Several studies showed that the combination of optimal cytoreductive operation and HIPEC is a&#xD;
      secure method of treatment. In comparison to operation and standard-chemotherapy it has a&#xD;
      significant positive influence on survival rates. A hyperthermal intraperitoneal chemotherapy&#xD;
      with Carboplatin is possible without severe side-effects.&#xD;
&#xD;
      The combination of optimal cytoreductive operation (according to Desktop II criteria), HIPEC&#xD;
      with Carboplatin and following platinum-based systemic chemotherapy should be carried out in&#xD;
      patients with platinum-sensitive recurrence.&#xD;
&#xD;
      Condition for applying HIPEC is reaching optimal cytoreduction (&lt;0.5 cm visible tumour rest&#xD;
      at the end of operation) and according to expert opinion a complicatin-free prolongation of&#xD;
      narcosis after finishing the operative intervention. HIPEC is carried out additionally to&#xD;
      standard therapy. If it can be carried out, the amount of systemically administered&#xD;
      patinum-based chemotherapy is reduced for one cycle.&#xD;
&#xD;
      This regime should be tested on safety in performance, quality of life for patients, and&#xD;
      consequences for the following systemic chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    actually limited personnel ressources&#xD;
  </why_stopped>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Elevation of side-effects and postoperative complication-rate</measure>
    <time_frame>24 months</time_frame>
    <description>Observation, classification and graduation of side-effects through NCI Common Terminology Criteria for Adverse Events version 4.03 [&quot;safety issue&quot;]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survey of quality of life per EORTC evaluated questionnaires</measure>
    <time_frame>24 months</time_frame>
    <description>Using EORTC -QLQ-C30 and EORTC QLQ-OV28, at study initiation, postoperative, before systemic chemotherapy and afterwards</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recording of PFS (progession free survival)</measure>
    <time_frame>24 months</time_frame>
    <description>Recording of PFS (progession free survival) of the patients in a time-span of 24 months [kein &quot;safety issue&quot;]</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <condition>Peritoneal Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <arm_group>
    <arm_group_label>HIPEC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If patient is eligible - secondary cytoreductive operation will be followed by HIPEC with 800 mg/m² body surface (KOF) Carboplatin with closed technique.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HIPEC</intervention_name>
    <description>secondary cytoreductive operation</description>
    <arm_group_label>HIPEC</arm_group_label>
    <other_name>Hyperthermal intraperitoneal Chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Hyperthermal Intraperitoneal Chemotherapy (HIPEC)</description>
    <arm_group_label>HIPEC</arm_group_label>
    <other_name>Carboplatin Accord</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Patients with platinum-sensitive recurrence after 12-48 months after platinum-based&#xD;
             firstline-chemotherapy of histological saved epithelial ovarian carcinoma, primary&#xD;
             peritoneal carcinoma or tube carcinoma with planned cytoreductive operation&#xD;
&#xD;
          -  The following histological types can be included: serous, endometrioide, clear cell or&#xD;
             undifferentiated carcinoma. Mixed epithelial carcinoma, malignant Brenner Tumour&#xD;
&#xD;
          -  No preceding recurrence chemotherapy&#xD;
&#xD;
          -  Preceding hormontherapy admitted. Concomitant antineoplastic antihormone-therapy&#xD;
             (Tamoxifen, Aromataseinhibitoren etc.) not admitted. Low dosed (physiological)&#xD;
             hormone-replacement-therapie (HRT) can be administered&#xD;
&#xD;
          -  Patients with maintenance therapy (e.g. Bevacizumab) permitted, assumed recurrence was&#xD;
             diagnosed 12 months after primary cytotoxic chemotherapy (also with maintenancetherapy&#xD;
             during chemotherapy) and last administration of maintenancetherapy happened min. 21&#xD;
             days before first study protocol intervention&#xD;
&#xD;
          -  Resectability R0 probably, fixed by Desktop II-criteria:&#xD;
&#xD;
          -  Cytoreductive operation at first-diagnosis of the carcinoma R0&#xD;
&#xD;
          -  Ascites &lt;500 ml&#xD;
&#xD;
          -  ECOG 0&#xD;
&#xD;
          -  R0 status (≤0,5 cm tumour rest) at the end of secondary cytoreductive operation&#xD;
&#xD;
          -  Eligibility for Standard systemic platinum-based combination chemotherapy after sec.&#xD;
             cytoreductive operation with or without HIPEC (investigators decision)&#xD;
&#xD;
          -  Bone marrow function: Haemoglobine ≥8.5 g/dL, Absol. neutrophile Granulocytes(ANC)&#xD;
             ≥1.000/mm3, Thrombocytes ≥ 100.000/mm3&#xD;
&#xD;
          -  Renal function: Serum Creatinin ≤1,5 times the ULN, calculated Creatininclearance&#xD;
             (GFR) ≥60ml/min&#xD;
&#xD;
          -  Liver function: Bilirubin ≤1,5 x&#xD;
&#xD;
          -  ALT, AST ≤3 x ULN&#xD;
&#xD;
          -  Adequate coagulation parameter: INR-value ≤1,5, aPTT ≤1,5 x ULN&#xD;
&#xD;
          -  For patients under fully-dosed/therapeutic Warfarin- or Phenprocoumontherapy INR&#xD;
             between 2-3 and aPTT &lt;1,2 x ULN&#xD;
&#xD;
          -  Neurol. Function: peripheral Neuropathy ≤Grade 2 (CTCAE v4.03 criteria)&#xD;
&#xD;
          -  In women with childbearing potential availability of a neg. serum pregnancy test 2&#xD;
             weeks before planned sec. cytored. operation + effective contraception during study&#xD;
             period guaranteed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No signed informed consent&#xD;
&#xD;
          -  Tumours with low malignant potential (Borderline-carzinomas)&#xD;
&#xD;
          -  Patients with preceding radiotherapy in abdomen and pelvis&#xD;
&#xD;
          -  Patients with preceding endometrial carcinoma will be excluded, except: Stage IA [no&#xD;
             low differentiated subtype (serous-papillary, clear cellular, FIGO grade 3)]&#xD;
&#xD;
          -  With the exception of non-melanoma skin cancer and other specific malignancies as&#xD;
             noted above, subjects with other invasive malignancies, who had any evidence of the&#xD;
             other cancer present within the last 3 years or whose previous cancer treatment&#xD;
             contraindicates this protocol therapy, are excluded&#xD;
&#xD;
          -  Known acute hepatitis&#xD;
&#xD;
          -  acute infectious disease with need for intravenous antibiosis&#xD;
&#xD;
          -  immunodeficiency&#xD;
&#xD;
          -  Active coronaryarterial disease: Myocardinfarct or instable Angina pectoris within 6&#xD;
             months before study inclusion: coronary artery disease in anamnesis can be included,&#xD;
             assumed a normal stress-electrocardiogram finding within 30 days before study&#xD;
             inclusion&#xD;
&#xD;
          -  Cardiac insufficiency NYHA ≥2 classif. of New York Heart Association&#xD;
&#xD;
          -  Hypertension ≥140/90 mm Hg&#xD;
&#xD;
          -  Poorly controlled cardiac arrythmia despite medication (patients with&#xD;
             frequencey-controlled atrial fibrillation can participate)&#xD;
&#xD;
          -  Peripheral vascular disease ≥grade 3 (e.g. symptomatic and affecting activities of&#xD;
             everyday-life, intervention or revision necessary)&#xD;
&#xD;
          -  Renal insufficiency Serumcreatininvalues ≥1,5 times the ULN or GFR &lt;60ml/min&#xD;
&#xD;
          -  Cerebrovascular disease in anamnesis&#xD;
&#xD;
          -  Patients with another severe medical problem-independent of cancer-which excludes&#xD;
             study participation&#xD;
&#xD;
          -  Known allergies to Carboplatin or Cisplatin&#xD;
&#xD;
          -  extended intraperitoneal adhesions at time of secondary cytoreductive operation, which&#xD;
             makes administration of intraperitioneal chemotherapy impossible&#xD;
&#xD;
          -  Life expectancy &lt;12 weeks&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lukas Hefler, Prim. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Krankenhaus der Barmherzigen Schwestern Linz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of gynaecology, Ordensklinikum Linz Ges.m.b.H, Barmherzige Schwestern</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 13, 2015</study_first_submitted>
  <study_first_submitted_qc>June 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2015</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

